ribociclib succinate at a glance
Medicine class
Targeted anticancer treatment; CDK4/6 inhibitor.
Treatment setting
Used with an aromatase inhibitor or, in specified advanced disease, fulvestrant.
Food
Tablets may be taken with or without food, but grapefruit must be avoided.
Tablet handling
Swallow whole; do not chew, crush, split or take damaged tablets.
What is ribociclib succinate used for?
Uses represented by the selected product include:
Adjuvant treatment, with an aromatase inhibitor, of hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence.
Treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in women, with an aromatase inhibitor or fulvestrant, either as initial endocrine-based treatment or after previous endocrine therapy.
For relevant premenopausal or perimenopausal patients—and men receiving adjuvant treatment—the accompanying aromatase inhibitor or endocrine therapy is combined with an LHRH agonist as specified in the licence.
How does ribociclib succinate work?
CDK4 and CDK6 help cells pass a key checkpoint before dividing. Ribociclib inhibits these enzymes, reduces phosphorylation of retinoblastoma protein and arrests susceptible cancer cells before DNA replication, slowing their proliferation. Endocrine therapy also limits hormone-driven growth signals.
How to take ribociclib succinate
Follow the treatment calendar and instructions supplied by the oncology team. Practical points include:
Swallow tablets whole with water; do not chew, crush or split them.
Do not take tablets that are broken, cracked or otherwise damaged.
They may be taken with or without food.
Take them at approximately the same time on each scheduled treatment day, preferably in the morning.
Avoid grapefruit, grapefruit juice and foods containing grapefruit.
Do not change the prescribed schedule or stop treatment without speaking to the oncology team.
ribociclib succinate side effects
Common or expected effects
- Low white-cell counts, including neutropenia and leukopenia
- Infections
- Nausea, diarrhoea, constipation or vomiting
- Tiredness, weakness or headache
- Abnormal liver blood tests
- Hair thinning or loss
- Cough or rash
- Anaemia
Get urgent medical advice
- Fever, chills, sore throat or mouth ulcers suggesting infection with a low white-cell count
- New or worsening cough, breathlessness, chest pain or fever suggesting pneumonitis or interstitial lung disease
- Yellow skin or eyes, dark urine, upper abdominal pain or unusual bruising suggesting liver injury
- Palpitations, marked dizziness or fainting suggesting a heart-rhythm problem
- Spontaneous bleeding or significant bruising
- Blistering or peeling skin, mouth or eye involvement, or a widespread rash with fever
ribociclib succinate in pregnancy
Ribociclib is not recommended during pregnancy because animal findings indicate potential fetal harm. Pregnancy status should be checked before treatment, and effective contraception is required during treatment and for at least 21 days after the final dose; contraceptive options should be discussed with the specialist team.
ribociclib succinate while breastfeeding
It is unknown whether ribociclib enters human milk, and harm to a breastfed infant cannot be excluded. Breastfeeding should be avoided during treatment and for at least 21 days after the final dose.
ribociclib succinate interactions
The oncology team and pharmacist should check prescribed, over-the-counter and herbal products before and during treatment.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, posaconazole, voriconazole, ritonavir and verapamil
Can substantially increase ribociclib exposure and toxicity; concomitant use should generally be avoided.
Strong CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin and St John’s wort
Can substantially reduce ribociclib exposure and may impair effectiveness; avoid concomitant use.
Medicines that prolong the QT interval, including amiodarone, sotalol, methadone, haloperidol and some antibiotics
May increase the risk of clinically important heart-rhythm disturbance and should generally be avoided.
Common questions about ribociclib succinate
Answers are fully visible for fast scanning and source review.
Is ribociclib succinate chemotherapy?
It is a targeted anticancer treatment rather than conventional cytotoxic chemotherapy. It selectively inhibits CDK4 and CDK6, proteins involved in cell division.
Why is ribociclib given with hormone therapy?
The treatments act on complementary growth pathways: endocrine therapy reduces hormone-driven signalling, while ribociclib blocks CDK4/6-mediated cell-cycle progression.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.